Publications by authors named "Carolina Heuser"
Objective: The LungFlag risk prediction model uses individualized clinical variables to identify individuals at high-risk of non-small cell lung cancer (NSCLC) for screening with low-dose computed tomography (LDCT). This study evaluates the cost-effectiveness of LungFlag implementation in the Spanish setting for the identification of individuals at high-risk of NSCLC.
Methods: A model combining a decision-tree with a Markov model was adapted to the Spanish setting to calculate health outcomes and costs over a lifetime horizon, comparing two hypothetical scenarios: screening with LungFlag versus non-screening, and screening with LungFlag versus screening the entire population meeting 2013 US Preventive Services Task Force (USPSTF) criteria.
Article Synopsis
- In 2020, atezolizumab-bevacizumab became the new standard treatment for first-line unresectable hepatocellular carcinoma (HCC), replacing sorafenib after a decade of use.
- The systematic literature review (SLR) and network meta-analysis (NMA) aimed to compare the effectiveness of atezolizumab-bevacizumab against other approved treatments for unresectable HCC.
- The analysis of 49 studies indicated that atezolizumab-bevacizumab likely offers better overall survival compared to most other treatments, although some results were inconclusive.